First, we use standard pathological information on DCIS grade (low-to-intermediate) and estrogen-receptor-positive status, similar to the eligibility criteria of ongoing prospective clinical trials for AS. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.